Background: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and their associated cas genes are sequence-specific DNA nuclease systems found in bacteria and archaea. CRISPR/Cas systems use RNA transcripts of previously acquired DNA (spacers) to target invading genetic elements with the same sequence, including plasmids. In this research we studied the relationship between CRISPR/Cas systems and multidrug resistance in Escherichia coli.
Introduction
Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) loci were first observed over 20 years ago and have since been found in the genomes of many bacteria and archaea. 1 These loci together with their associated Cas proteins comprise a system, collectively known as CRISPR/Cas, which has been described as providing adaptive immunity for bacteria, targeting potentially deleterious or costly invading DNA such as phages or plasmids. CRISPR loci consist of short 21-47 bp repeats separated by similarly sized non-repeating sequences called spacers. 2 The repeat arrays are often, but not always, associated with cas genes, which encode the proteins involved in the function of the CRISPR/Cas system. The CRISPR/Cas system leads to the enzymatic cleavage of doublestranded DNA in precise sites determined by the sequence of the spacer. 3 The process can be divided into two stages; acquisition and interference. In the acquisition stage, Cas1 and Cas2 proteins scan invading DNA for a short 3-6 bp motif (called the Protospacer Adjacent Motif or PAM). Sequences immediately next to the PAM are processed and integrated into the CRISPR array; these spacers are then transcribed and processed into CRISPR RNA (crRNA), and this RNA is used in the interference stage to guide the Cas nuclease complex to cleave complementary DNA. 1 With recent attention focused on the genetic engineering potential of CRISPR/Cas, its natural role has received less attention. The existence of an adaptive immune system that rids bacteria of mobile genetic elements (MGEs) is paradoxical in terms of survival. Indeed, the ubiquitous distribution of MGEs among bacterial species suggests that CRISPR systems are not always functional, or that they may have other roles such as the regulation of gene expression 4 and/or as yet undiscovered roles. In some environments, host bacteria clearly benefit from plasmid-encoded traits such as antimicrobial resistance, and possession of CRISPR systems to rid the cell of such plasmids is likely to be rapidly selected against. The assumption that CRISPR functions as an immune system has been called into question in Escherichia coli. 5 We set out to explore this paradox. Two subtypes of CRISPR are known in E. coli, Type I-E and Type I-F. 6 In both types, the genes are clustered and closely flanked by two repeat arrays each: CRISPR1 and CRISPR2 for Type I-E, and CRISPR3 and CRISPR4 for I-F. Both systems are similar, but the Type I-E system has eight genes, whereas Type I-F has six. 7 The functionality of the Type I-E system has been brought into question due to the finding that Type I-E cas genes are repressed by the global regulator H-NS under laboratory conditions. 8 Conversely, Type I-F cas genes have been shown to be constitutively expressed. 9 Due to the spacer content of the two systems, it has previously been hypothesized that the Type I-E system may be specialized in targeting bacteriophages, whereas the Type I-F system is more associated with plasmids. 6 In this study, we examine the relationship between CRISPR and antimicrobial resistance plasmids in E. coli by comparing the prevalence of CRISPR Type I-E and I-F systems in antimicrobialsusceptible and antimicrobial-resistant isolates. Additionally, by investigating expression of Type I-F cas genes, we aim to gain an insight into the activity of these systems and their potential interference with natural antimicrobial resistance plasmids.
Methods

E. coli isolates and antimicrobial susceptibility testing
A total of 178 clinical E. coli isolates, derived from three sources, were available for the study. Isolates were split into two groups: MDR isolates, 10 comprising 96 isolates, and fully susceptible isolates, comprising 82 isolates, based on known susceptibility testing results to 10 or more antimicrobials. RFH isolates were picked at random from available fully susceptible or MDR E. coli isolates from the urine bench. The isolates from south-west England represented the first 50 fully susceptible isolates in a larger collection forming part of another study (1 was later removed due to resistance). All isolates were subjected to additional susceptibility testing to antimicrobials commonly associated with plasmid-acquired genes (ampicillin, gentamicin, tetracycline, ciprofloxacin, chloramphenicol and sulfamethoxazole) using the EUCAST disc diffusion method. All isolates are listed in Table S1 (available as Supplementary data at JAC Online).
PCR and DNA sequencing
PCR was used to screen for four known CRISPR arrays with primers from Touchon et al. 5 (listed in Table 1 ). PCRs were prepared using HotStar Taq MasterMix (Qiagen) according to the manufacturer's instructions (12.5 lL of MasterMix, 0.2-1 mM of each primer and 20-100 ng of DNA up to 25 lL total volume). PCR products were visualized in agarose/ethidium bromide gels under UV light. The presence of CRISPR3 and CRISPR4 arrays was confirmed with Sanger DNA sequencing (Beckman Coulter Genomics) followed by CRISPR identification using CRISPRfinder. 2 
Analysis of E. coli by phylogrouping, MLST and plasmid replicon typing
Phylogenetic groups were determined using multiplex PCR according to the revised method of Clermont et al. 12 and isolates that were unclassified according to the method were reconfirmed to be E. coli by MALDI-TOF MS.
MLST was also performed on Type I-F CRISPR-containing isolates using the seven-gene Achtman method.
13 O25b-ST131 clones were detected using PCR.
14 PCR-based replicon typing was used to screen CRISPR I-F-containing E. coli for the presence of IncF and IncI group plasmids. 15 
Spacer analysis
CRISPRfinder 2 was used to determine the number and sequences of the spacers within CRISPR3 and CRISPR4 repeat arrays. Nucleotide BLAST and CRISPRTarget 16 were used to search for matching sequences for Type I-F spacers and a subset of Type I-E spacers. An identity score of 29 was used as a lower threshold for plasmid matches of interest, excluding matches to CRISPR regions from other isolates.
RT-PCR for expression analysis
RT-PCR for Type I-F csy1 and cas1 was performed using a One Step RT-PCR kit (Qiagen) using previously described primers ( Table 1 ). The housekeeping gene rpsL was used as a control. RNA was extracted from bacteria in the logarithmic phase using an RNeasy minikit (Qiagen) and treated with DNase using Turbo DNA (Ambion) according to the manufacturer's instructions. Extracts were confirmed to be devoid of detectable DNA with PCR using a HotStar Taq kit (Qiagen).
Statistics
Results were analysed using GraphPad Prism 7. A significance level of a " 0.05 was used for all statistics. Fisher's exact test was used for comparisons of CRISPR presence between the susceptible and resistant isolates.
Results and discussion
All 178 E. coli isolates were screened for four CRISPR arrays (CRISPR1-4) found in this species. Overall, over half of the E. coli isolates had at least one of the screened CRISPR arrays (53.9%), and Type I-E repeat arrays (CRISPR1 and/or 2) were more common (39.9%) than Type I-F repeats (CRISPR3 and/or 4) (15.7%). The overall distribution of CRISPR array types differed significantly Aydin et al.
between susceptible and MDR groups (P , 0.0001); CRISPR1 and 2 arrays were overwhelmingly the most prevalent amongst resistant isolates, whereas in susceptible isolates approximately equal numbers of both array types (CRISPR1/2 or CRISPR3/4) were found (Figure 1 ). Type I-E and Type I-F repeats were largely mutually exclusive among the isolates; only 4 out of the 178 isolates studied had repeats associated with both CRISPR types, in line with previous findings. 5 None of the isolates had all four repeat arrays. In addition to screening for the individual repeat arrays, isolates that were shown to have Type I-F repeats (CRISPR3 and CRISPR4) were also screened for Type I-F cas genes. Out of the 82 susceptible isolates, 18 (22.0%) had Type I-F systems, defined here as having CRISPR3 and CRISPR4 as well as the associated genes, and an additional 8 (9.8%) had only CRISPR3 repeat arrays, but without the cas genes. This differs significantly from the resistant isolates (P , 0.0001) where only 2 isolates out of 96 (2.1%) had Type I-F systems and none had CRISPR3 on their own. Type I-F overrepresentation in susceptible isolates was also demonstrated in only the RFH subset of isolates collected from the same hospital and over the same time period (P " 0.0108). 21.2% of the 33 susceptible RFH isolates had CRISPR I-F, whereas only 3.5% of the 57 resistant RFH isolates had the system. None of the highly resistant Egyptian isolates had CRISPR3 or 4.
There were a total of 65 distinct CRISPR3 spacers and 39 distinct CRISPR4 spacers with no overlap between the two arrays in terms of spacer content. Some spacers were common and appeared in multiple non-clonal isolates, including both susceptible and resistant isolates (Table 2 and Figure 2 ). Type I-E repeats from 49 susceptible isolates were also sequenced for comparison. Interestingly, there were 152 and 117 distinct spacers for CRISPR1 and CRISPR2, respectively, which is greater than the number of distinct spacers for CRISPR3 and CRISPR4 for the entire group of 178 isolates. However, none of the CRISPR1-and CRISPR2-associated spacers corresponded to known plasmids and only one corresponded to a known phage. Most spacers were cryptic with no homology to any known genes. This is in contrast to the work of D ıez-Villaseñor et al., 17 who reported a much larger proportion of spacers with a known origin. On the other hand, nucleotide BLAST for the Type I-F spacers revealed that five of the spacers matched conserved regions within IncFII-, IncFIB-and IncI1-type plasmids with a minimum of 97% homology (31/32 nucleotides) ( Table 2) . One spacer corresponding to klcA, encoding a putative antirestriction protein, appeared in 20 isolates in total. The klcA gene is conserved among IncI1 and IncFII plasmid scaffolds, including those associated with the epidemic E. coli ST131, typified by the CTX-M-15-encoding plasmids pEK516 and pEK499. 18 Interestingly, three of the spacers identified (2, 3 and 4 in Table 2 ) are found in the same, largely cryptic, region, which is shared between IncI1 and IncFII plasmids. PCR-based screening for plasmid replicons confirmed the absence of plasmids corresponding to the spacer content of susceptible E. coli isolates containing Type I-F CRISPR loci. The contrast between the spacer content between Type I-E and I-F systems supports the hypothesis that the systems have different functions within E. coli with the Type I-F seemingly being associated more with plasmids.
Phylogrouping was performed for all 178 isolates and their phylogroup composition breaks down as follows: A 10.7%, B15.6%, B255.1%, C 2.3%, D 14.6%, E 2.8%, F 7.9% and unclassified 1.1%. The results confirmed a previously reported 17 association between CRISPR subtype and phylogenetic groups. CRISPR I-F systems were only found in B2 group isolates, whereas I-E systems never N o n e C R I S P R 1 C R I S P R 2 C R I S P R 3 C R I S P R N o n e C R I S P R 1 C R I S P R 2 C R I S P R 3 C R I S P R Figure 1 . Proportion of E. coli isolates with CRISPR1, 2, 3 and 4 repeat arrays within the susceptible and MDR groups. Overall the two groups had a significantly different distribution of CRISPR arrays (P , 0.0001). CRISPR1 and 2 and CRISPR3 and 4 are often, but not always, found in pairs. Five spacers that correspond to plasmid sequences were found using nucleotide BLAST in strains containing CRISPR3 and CRISPR4, including isolates that had repeat arrays, but no I-F genes.
Type I-F CRISPR/Cas and antimicrobial susceptibility in E. coli JAC appeared in B2 isolates. However, lone CRISPR3 arrays without cas genes or CRISPR4 were detected in phylogroups A, D, E and F (Table S1 ). Our results show that B2 isolates are more common in the susceptible group (65.4%) than in the resistant group (49.0%). Since Type I-F systems only appear in the B2 group, we analysed Type I-F presence within the B2 group only and found a significant difference between susceptible and MDR isolates within B2 (P " 0.0001) (Figure 3) . Further, MLST analysis was performed on all isolates with Type I-F systems as well as 10 randomly selected susceptible isolates without Type I-F CRISPR. All isolates underwent PCR screening for the O25b-ST131 epidemic clone. 14 The MLST types of Type I-F-positive isolates suggested clustering within particular STs, with 9 of the 20 isolates with Type I-F systems belonging to the ST95 clonal complex, including one of the resistant isolates with Type I-F systems. The second most common ST among Type I-F isolates was ST141 (3/20) . Plasmidcorresponding spacers were largely limited to these two STs (Figure 2 ). The MLST types of isolates without I-F CRISPR systems were representative of urinary E. coli found in other studies (Table S1 ). 19 A previous study found that unlike the Type I-E system, Type I-F genes can be expressed under laboratory conditions. 9 We therefore used RT-PCR to investigate the expression of the csy1 and cas1 genes at the log phase of growth in seven Type I-F isolates (six from the susceptible group and one from the MDR group). These two genes are the first in the two putative transcriptional units of the Type I-F cas genes. 9 In all seven of the Type I-F strains tested, both transcriptional units were expressed in the log phase of growth.
In this work we show that the presence of the Type I-F CRISPR systems is strongly associated with antimicrobial susceptibility in E. coli. Reinforcing previous research, 5, 17 we also demonstrate that Type I-F systems are only typically associated with the B2 phylogenetic group. However, our results are in contrast to a previous study, which did not show an association between the distribution of CRISPR and antimicrobial resistance plasmids in E. coli. 20 When only considering the B2 group, which is the only group that can contain Type I-F genes, the presence of the Type I-F system is still strongly associated with antimicrobial susceptibility. We also show Table 2 . MLST types of all isolates with complete Type I-F systems are listed. Aydin et al.
that Type I-F genes are expressed in a number of clinical isolates of E. coli and therefore theoretically capable of interfering with antimicrobial resistance plasmids. Indeed, a study by Almendros et al. 9 demonstrated that an isolate with an expressed Type I-F system was also capable of interfering with plasmid constructs containing matching spacers.
Previous work has shown that some B2 lineages such as ST131 are associated with antimicrobial resistance. 21, 22 None of the ST131 isolates included within our study contained Type I-F systems. What was more striking was the finding that CRISPR3 and CRISPR4 arrays incorporated spacer sequences derived from IncFII and IncI1 plasmid scaffolds commonly linked to resistant E. coli clones such as ST131. ST95 strains are often underrepresented in resistant groups of E. coli 23, 24 and our data suggest that CRISPR may be a contributing factor, given that 9/20 of the Type I-F-positive isolates reported here belonged to the ST95 clonal complex. We suggest that B2 strains with active Type I-F CRISPR systems may be interfering with the uptake or survival of antimicrobial resistance plasmids within the isolate, hence helping to keep them susceptible to antimicrobials.
The observation that some of these spacers still persist in multiple isolates and different STs may be an indication that they are advantageous, particularly since the spacers can correspond to more than one plasmid. In environments where antimicrobials are scarce or absent, plasmids may confer a fitness cost, 25 and in these conditions, B2 strains with Type I-F systems may have an advantage. While we did find two MDR isolates with Type I-F spacers that correspond to antimicrobial resistance plasmids, this could be explained by the fact that CRISPR systems have been shown to have leakage and are not functionally perfect even with exact spacer matches and optimal PAMs. 9, 26 There is also the possibility that the system has been deactivated as reported in Staphylococcus epidermis.
25
Taken together, our findings suggest a role for Type I-F CRISPR in the distribution of antimicrobial resistance among E. coli B2 lineages.
